Source:http://linkedlifedata.com/resource/umls/id/C1619629
NCI: A synthetic, orally bioavailable, achiral, tridentate triazole derived from salicylic acid with iron-chelating activity. Deferasirox chelates iron at a 2:1 (ligand:iron) ratio. Because of its oral availability and long plasma half-life, this agent may be superior to desferrioxamine (desferal, DFO), which is orally inactive and has a short plasma half-life.,PDQ: A synthetic, orally available, achiral, tridentate triazole derived from salicylic acid with iron chelator properties. Deferasirox chelates iron at a 2:1 (ligand:iron) ratio. Because of its oral availablity,and long plasma half-life, this agent may be superior to desferrioxamine (desferal, DFO), which is orally inactive and has a short plasma half-life. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=435986&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=435986&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dic